Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Biomarker Testing

Find an overview of funded biomarker testing in Ontario. Information listed includes diagnostic, predictive and prognostic markers, as well as a summary of testing sites.

Disponible en anglais seulement. Vous pouvez demander un version française.

Funded Biomarker Testing

3 items

Reflex testing on newly diagnosed cases of NSCLC (adenocarcinoma/non-squamous).

Funded Biomarker Disease Site: Lung

Biomarker: PD-L1, ALK, EGFR, ROS1, BRAF, MET (Met Skipping), RET, FGFR1, HER2 (ERBB2), KRAS, PIK3CA, NTRK1, NTRK2, NTRK3 Optional for 22/23: NRG1, TP53, STK11, KEAP1

Testing Method:Panel

Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System

Reflex testing on newly diagnosed cases of NSCLC (squamous).

Funded Biomarker Disease Site: Lung

Biomarker: PD-L1

Testing Method:Immunohistochemistry (IHC)

Testing on patients previously diagnosed with locally advanced or metastatic NSCLC who have progressed on or after EGFR TKI therapy.

Funded Biomarker Disease Site: Lung

Biomarker: Acquired EGFR T790M

Testing Method:Sequencing